论文部分内容阅读
利奈唑胺是1987年合成的第一个噁唑烷酮类抗生素,化学名称为(S)-N[[3-[3-氟-4-(4-吗啉基)苯基]-2-氧代-5-恶唑烷基]-乙酰胺。它通过与细菌50S亚基附近界面的30S亚基结合,抑制mRNA核糖体链接,阻止70S初始复合物的形成,从而抑制细菌蛋白质合成,发挥杀菌和抑菌的双重作用。利奈唑胺对革兰阳性菌的抗菌谱广,包括对甲氧西林敏感或耐药的金黄色葡萄球菌(MSSA或MRSA)、耐甲氧西林表皮葡萄球菌(MRSE)、其他凝固酶阴性葡萄球菌(CNS)、对万古霉素敏感及耐药的肠球菌、对青霉素敏感及耐药的肺
Linezolid is the first oxazolidinone antibiotic synthesized in 1987 with the chemical name of (S) -N [[3- [3-fluoro-4- (4- morpholinyl) phenyl] -2- Oxo-5-oxazolidinyl] -acetamide. It binds to the 30S subunit in the vicinity of the 50S subunit of bacteria to inhibit the mRNA ribosomal link and prevent the formation of the initial 70S complex, thereby inhibiting bacterial protein synthesis and exerting the dual role of bactericidal and bacteriostatic effects. Linezolid antibacterial spectrum of gram-positive bacteria, including methicillin-sensitive or resistant Staphylococcus aureus (MSSA or MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), other coagulase-negative staphylococcus (CNS), vancomycin-resistant and resistant enterococci, penicillin-sensitive and resistant lungs